Nxera Pharma (TYO:4565) will receive a $8.6 million milestone payment from Centessa Pharmaceuticals, a unit of American pharmaceutical company Eli Lilly, following a late-stage development milestone, according to a Thursday filing with the Tokyo Exchange.
The biopharmaceutical company said the milestones are linked to Centessa's selective orexin receptor 2 agonist portfolio under its research collaboration with Centessa.